Many other IVF programs in the US are still relying heavily on judging an embryo’s potential to implant by how it looks – essentially judging a book by its cover. But at RMANJ, our evidence-based approach demands we do more.
RMANJ has developed a unique, rapid and scientific method to improve the embryo selection process, called SelectCCS (comprehensive chromosome screening). This one-of-a-kind 24-chromosome screening platform identifies whether embryos are euploid (normal number of chromosomes or 46 with 23 obtained from each parent) or aneuploid (abnormal number of chromosomes).
Since we now know errors can occur with all 23 pairs of chromosomes, our screening process is comprehensive by counting all chromosomes at the molecular level and more effective than previous testing processes that only count a handful of chromosomes. Current data suggests that 50-70% of miscarriages are due to embryos with too few or too many chromosomes. At the same time we know that the frequency of aneuploidy increases with age.
Using a more comprehensive and evidence-based approach like SelectCCS during the embryo selection process can improve safety and efficacy of your IVF cycle. RMANJ’s SelectCCS process has demonstrated to be 98% accurate2,3.
Rather than waiting several hours or even days for test results, the SelectCCS process means we can biopsy, test, and transfer an embryo in a single day, reducing the anxiety waiting for results while improving accuracy and chance for success.
Additionally, the SelectCCS process makes the promise of single embryo transfer (SET) a reality, providing uncompromising success rates without complications often associated with twin pregnancies and deliveries.
“Advances in screening technology that allow us to rapidly and safely determine if an embryo is chromosomally normal now make ‘SET’ a more viable pathway to pregnancy for couples undergoing IVF. We can reduce the risk of twins, which tend to be more complicated pregnancies, but thanks to improved freezing technology not reduce the chance of having two children if that’s what a couple wants in the long run.”
Eric J. Forman, MD, FACOG, BEST Trial Investigator
1. Scott RT, Jr., Upham K, Forman E, Hong K, Scott K, Taylor D, Tao X, Treff NR. Blastocyst biopsy with comprehensive chromosome screening and fresh embryo transfer significantly increases in vitro fertilitzation implantation and delivery rates; a randomized controlled trial. Fertil Steril 2013. In Press.
2. Richard T. Scott Jr., M.D., Kathleen Ferry, B.S., Jing Su, M.S., Xin Tao, M.S., Katherine Scott, M.S., and Nathan R. Treff, Ph.D. Comprehensive chromosome screening is highly predictive of the reproductive potential of human embryos: a prospective, blinded, nonselection study. Fertility and Sterility. April 2012; 97(4):870-5.
3.Forman, E.J., Tao, X., Ferry, K.M., Taylor, D., Treff, N.R., Scott, R.T. Single Embryo Transfer with Comprehensive Chromosome Screening Results in Improved Ongoing Pregnancy Rates and Decreased Miscarriage Rates. Human Reproduction. April 2012; 27(4):1217-22.
Please note that a comparison of clinic success rates may not be meaningful because a patient’s medical characteristics, treatment approaches and entrance criteria for ART may vary from clinic to clinic. We encourage you to learn more at www.sart.org.